Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique
Telomeric Abnormalities in Benign and Malignant Colorectal Diseases by Fluorescent in Situ Hybridization Technique
1 other identifier
observational
80
0 countries
N/A
Brief Summary
Colorectal carcinoma is a heterogeneous disease that is caused by the interaction of genetic and environmental factors. colorectal carcinoma encompasses a complex disease with different molecular pathways and biological characteristics arising from a multi-step process that implicates several genetic and epigenetic events . The multi-step genetic model involves the loss of function of tumor suppressor genes, such as adenomatous polyposis coli (APC), Telomeres could be a promising marker due to the fact that their lengths change in the colorectal polyp-carcinoma sequence . Moreover, telomere length (TL) is altered in blood cells in patients with colorectal carcinoma
- These findings could suggest that changes in TL may take place before the development of the tumor . The two main forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) are characterized by chronic intestinal inflammation and risk of progression to colon cancer. One proposed cause of the latter characteristic is chromosome instability, since the rearrangement of genetic material can lead to activation of oncogenes, loss of tumor suppressor genes and other changes that lead to uncontrolled cell growth. Chromosome instability is particularly associated with UC and has been observed in colon epithelial cells and peripheral blood mononuclear cell. Since genomic instability in peripheral blood mononuclear cells (PBMCs) has been used as a biomarker for global cancer risk in a number of diseases, the latter observation suggests the possibility of a chromosome instability syndrome in UC that could affect all tissues. One possible cause of chromosome instability is telomere dysfunction .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2017
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 3, 2017
CompletedFirst Posted
Study publicly available on registry
July 6, 2017
CompletedStudy Start
First participant enrolled
August 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2019
CompletedJuly 7, 2017
July 1, 2017
1 year
July 3, 2017
July 5, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
presence of telomeric abnormalities
measure percentage of telomeric abnormalities in benign and malignant colorectal diseases
one year
Study Arms (3)
control group
taking blood samples from apparently healthy people
benign colorectal
taking blood samples from patients
malignant colorectal
taking blood samples from patients
Interventions
taking blood samples and measure telomeric abnormalities
Eligibility Criteria
all patients with colorectal benign or malignant disease
You may qualify if:
- Adult age group ˃ 18 years.
- Newly diagnosed cases (no previous treatment).
- No treatment was taken for HCV infection.
You may not qualify if:
- age group \< 18 years.
- Patients with malignancy of other type.
- Patients not diagnosed by endoscopy or biopsy (not surely diagnosed).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Bosman F, Yan P. Molecular pathology of colorectal cancer. Pol J Pathol. 2014 Dec;65(4):257-66. doi: 10.5114/pjp.2014.48094.
PMID: 25693079RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
fatma magdy zidan, residant
South Egypt Cancer Institute
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principle investigator
Study Record Dates
First Submitted
July 3, 2017
First Posted
July 6, 2017
Study Start
August 1, 2017
Primary Completion
August 1, 2018
Study Completion
August 1, 2019
Last Updated
July 7, 2017
Record last verified: 2017-07
Data Sharing
- IPD Sharing
- Will not share